• Advocate on behalf of pharmaceutical benefit management practices impacted by direct and indirect remuneration and point of sale rebates related to the Medicare Part D prescription drug benefit program. In addition, monitor Medicare payment issues concerning home infusion, the Medicare Extenders package and S. 870, the Chronic Care Act of 2017.
• Advocate for the protection of PBM business methods and corresponding health savings.
• Promote health savings account reforms, including first-dollar coverage of chronic disease medicines as well as services offered at retail health clinics. Advocate for a lower domestic corporate tax rate as proposed under HR 1, the "Tax Cuts and Jobs Act."
• Engage with policymakers on proposals related to pharmaceutical pricing, substance abuse monitoring programs and information technology advancements.

Duration: November 18, 2013 to December 31, 2017

General Issues: Medicare/Medicaid, Pharmacy, Taxation/Internal Revenue Code, Health Issues, Food Industry (Safety, Labeling, etc.), Budget/Appropriations, Labor Issues/Antitrust/Workplace

Spending: about $532,500 (But it's complicated. Here's why.)

It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.

Agencies lobbied since 2013: U.S. Senate, House of Representatives